English (United States)
 

2013 Lung Cancer Conference - Lung Cancer Treatment in the Era of Personalised Medicine

18/02/13
reduce font Size enlarge font Size print content
 
NWI0035OK80JG210.jpg

The 2nd LUNG CANCER CONFERENCE will bring together in Luxembourg some of the world leading experts in lung cancer to discuss recent advances and to explore new avenues for research.

Lung cancer remains probably the most challenging area of cancer research. Despite years of research into new treatments, the survival rate from lung cancer remains one of the lowest of all cancers. At the dawn of personalised medicine, huge hopes rest upon new strategies capable of better selecting patients for targeted drugs as well as on new strategies capable of interfering with the molecular mechanisms of this disease. The objective of this scientific conference is to bring together in Luxembourg some of the world leaders in lung cancer to discuss recent advances and to explore new avenues for research.
The first Lung Cancer Conference (LCC) was organised in 2011 and gathered an outstanding panel of speakers composed of world leaders in lung cancer. The conference exceeded expectations by attracting over 200 participants, including scientists, clinicians, post-docs, students, and senior executives from throughout Europe.

The LCC is the result of the creation by the Luxembourg government in 2008 of a major new research initiative in personalised medicine. This new programme contains three closely integrated components, which are now offering a unique infrastructure that can support translational research and clinical studies in Luxembourg.

  1. A project in lung cancer at CRP- Santé and in collaboration with the Partnership in Personalized Medicine (PPM) in the United States.
  2. The creation of the IBBL (Integrated BioBank of Luxembourg) in collaboration with the Translational Genomics Research Institute (TGen) in Phoenix, Arizona.
  3. The Luxembourg Centre for Systems Biomedicine (LCSB) at the University of Luxembourg and in collaboration with the Institute for Systems Biology in Seattle, Washington.


The organisers of the LCC are members of the Luxembourg Personalised Medicine Consortium and the conference organising committee is composed of members involved in the lung cancer project.
All the details are available here: http://www.lungcancerconference.lu/
 

Who should register?

Healthcare professionals who wish to be part of a unique network, providing access to up-to-date, accurate and validated information about clinical research.

Investigators and study staff who wish to be part of a unique network, in order to stay abreast of clinical trials taking place in Luxembourg and who are willing to further develop their competencies.